NCT02646098View on ClinicalTrials.gov

CD34+ Selected ASCT for Aggressive Lymphomas

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 2, 2015

Primary Completion Date

October 11, 2018

Study Completion Date

November 30, 2023

Conditions
Malignant Non-Hodgkin Lymphomas
Interventions
PROCEDURE

CD34+ cell selection

CD34+ cell selection applying a CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany). This method for CD34+ cell selection will be used in this study and is considered as the standard treatment.

Trial Locations (1)

3010

Department for Medical Oncology; University Hospital/Inselspital, Bern

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT02646098 - CD34+ Selected ASCT for Aggressive Lymphomas | Biotech Hunter | Biotech Hunter